European data on PCa assay comparable to U.S. findings
Results presented at the EAU Annual Congress bolster the Prolaris test’s efficacy in determining disease aggressiveness.
New data show that the Prolaris prostate cancer test found more than 50% of men had a risk profile that was either lower or higher than would be expected using clinical pathology, suggesting that the pattern of aggressiveness for European and U.S. prostate cancer patients is consistent, according to a recent study.
RELATED: Targeted biopsy, PSA ‘choice’ among best-read articles
Findings from the EMPATHY-P clinical study of Prolaris (Myriad Genetics, Inc., Salt Lake City) were presented at the European Association of Urology annual congress in Madrid, Spain.
The authors evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in newly diagnosed patients in Italy, Germany, Spain, Switzerland, and the United Kingdom. The patients' biopsy samples also were evaluated using standard clinical pathology methods (D'Amico/AUA risk stratification), which were then compared to the Prolaris test results.
The Prolaris test found 52% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology, according to a press release from Myriad Genetics. The company said this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology. Specifically, EMPATHY-P demonstrated that the Prolaris test score found 22% of the European patients had less aggressive prostate cancer and 20% had more aggressive prostate cancer compared to standard clinical pathology measurements, compared with 18% and 33% in the U.S. Prostate Biopsy Research study, respectively.
ALSO SEE - RARP vs. open: Costs, morbidity compared in huge study
"Our data showed comparable results for both European and U.S. patients. In both groups, men with a low Prolaris score are good candidates for active surveillance, while patients with a high Prolaris score may need more aggressive care,” said senior author Colin Hayward, MD, of Myriad Genetics, in the release.
Want more Urology Times? Continue to the next page.
Check out these recent Urology Times articles:
Workplace exertion among factors linked to male infertility
Study uncovers 400% cost difference in BPH treatments
Race a factor in prostate cancer risk reclassification
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
